3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Colorectal Neoplasms
10
Breast Neoplasms
9
Colonic Neoplasms
6
Carcinoma, Non-Small-Cell Lung
5
Rectal Neoplasms
4
Lung Neoplasms
4
Head and Neck Neoplasms
4
Adenomatous Polyposis Coli
4
Sarcoma
3
Glioblastoma
3
Central Nervous System Neoplasms
3
Paranasal Sinus Neoplasms
2
Neoplasms
2
Mouth Neoplasms
2
Melanoma
2
Laryngeal Neoplasms
2
Gliosarcoma
2
Breast Carcinoma In Situ
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Triple Negative Breast Neoplasms
1
Tobacco Use Disorder
1
Stomatitis
1
Smoldering Multiple Myeloma
1
Smoking
1
Recurrence
1
Prostatic Neoplasms
1
Prostatic Hyperplasia
1
Precancerous Conditions
1
Interventions
Sirolimus
5
Everolimus
4
carbon-11 acetate
1
Sugars
1
Simvastatin
1
Resveratrol
1
Octreotide
1
Letrozole
1
Imatinib Mesylate
1
Hydroxychloroquine
1
Celecoxib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Lymphangioleiomyomatosis
×
Celecoxib
×
Clear all
NCT02484664
2022-01-20
COLA
Brigham and Women's Hospital
Phase 2
Completed
12 enrolled
11 charts